Abstract
BackgroundImmune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma. However, there is a high unmet need for patients who progress on these therapies and combination therapies are...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have